EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Amgen's enterprise value is $197,585 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $15,284 Mil. Therefore, Amgen's EV-to-EBITDA for today is 12.93.
The historical rank and industry rank for Amgen's EV-to-EBITDA or its related term are showing as below:
AMGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.21 Med: 11.84 Max: 19.97
Current: 12.93
During the past 13 years, the highest EV-to-EBITDA of Amgen was 19.97. The lowest was 8.21. And the median was 11.84.
AMGN's EV-to-EBITDA is ranked better than 53.22% of 729
companies
in the Drug Manufacturers industry
Industry Median: 13.83
vs AMGN: 12.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2025-06-30), Amgen's stock price is $279.21.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $10.960. Therefore, Amgen's PE Ratio (TTM) for today is 25.48.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Amgen EV-to-EBITDA Historical Data
The historical data trend for Amgen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amgen's EV-to-EBITDA falls into.
Amgen's current Enterprise Value is $197,585 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $15,284 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amgen's share price for today is $279.21.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Amgen's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 